Saperconazole (R66905)

Cell experiment:

A total of 279 Aspergillus isolates are tested in vitro; 221 of these are A. fumigatus. The inoculum consists of a standardized 4 mm2 culture block containing hyphae and spores for tubes with 5 mL of medium supplemented with drug solution or with solvent[2].

Animal experiment:

Male immunocompetent (normal) or immunocompromised pigs weighing 500 g (±50 g) are infected intravenously (i.v.) with 25,000 CFU of A.fumigatus B19119 per g of body weight. The animals are treated orally with Saperconazole, ketoconazole, or fluconazole dissolved in polyethylene glycol 200 (PEG 200). The treatment is given once daily for 14 consecutive days, starting on the day of infection or on day 1, 2, 3, or 4 after infection. Saperconazole, dissolved in dimethyl-β-cyclodextrin and in hydroxypropyl-β-cyclodextrin is also administered i.p. and i.v. Pigeons with a mean weight of 400 g (±30 g) are infected i.v. in a wing vein with 7,800 CFU of A.fumigatus B19119 per g of body weight. Saperconazole dissolved in PEG 200 is administered by gavage at 0, 2.5, 5, or 10 mg/kg starting on the day of infection and continued once daily for 14 consecutive days[2].

References:

[1]. Otcenásek M, et al. Susceptibility of clinical isolates of fungi to saperconazole. Mycopathologia. 1992 Jun;118(3):179-83.
[2]. VVan Cutsem J, et al. Oral and parenteral therapy with saperconazole (R 66905) of invasive aspergillosis in normal and immunocompromised animals. Antimicrob Agents Chemother. 1989 Dec;33(12):2063-8.